Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 229

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 229
---
 and operate without infringing the valid and enforceable patents and proprietary rights of other
parties.

As of the date hereof, we are
the patentee of a number of provisional and non-provisional patent applications, both on our proprietarily developed projects and improvement
to our in-licensed projects.

The following table sets forth
a list of our patent rights as of the date hereof related to our Lead Projects; SACT-1 is a proprietary technology not subject to any
license agreement:

| Project Company/Project name |     | Ownership Type                                                 |     | Licensor(s)       |     | Licensee                       |     | Licensed/IP Rights                                                                                            |     | Patent Expiration                                                                  
 Dates                                                                              |
| Acticule/ALS-4               |     | Exclusive Patent License Agreement, dated October 18, 2017     
 First Amendment to Exclusive License Agreement, dated June 7,  
 2018                                                           
 Second Amendment to Exclusive License Agreement dated July 10, 
 2019                                                           
 Exclusive Patent License Agreement dated January 11, 2019      |     | Versitech Limited |     | Acticule Life Sciences Limited |     | Exclusive licensee: 2 pending U.S. applications (16/867,540 and 17/006,985), 2 pending applications in Canada |     | The licensed IP rights include granted patents in the U.S. and                     
 pending patent applications in the U.S., and Canada.                               
 The U.S. patents will expire in 2038; any other patent based                       
 on the pending application, if granted, will have a 20-year patent term from 2018. |
| SACT-1                       |     | Self-owned Patent                                              |     | N/A               |     | N/A                            |     | U.S. Patent No. 11,166,952 & U.S. Patent No. 11,571,422                                                       |     | Both patents expire on November 27, 2040.                                          |

Because of the extensive time
required for clinical development and regulatory review of a drug we may develop, it is possible that, before any of our drug candidates
can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing
any advantage of any such patent. If appropriate, the Company may seek to extend the period during which it has exclusive rights to a
product by pursuing patent term extensions and marketing exclusivity periods that are available from the regulatory authorities of